Sema4 Holdings Corp - Units (1 Ord Share Class A & 1/3 War)
CMLFU
Get informed when a big investor buys or sells
+ FollowShare Statistics
| Market cap | $10.31 Billion |
|---|---|
| Enterprise Value | $10.29 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.73 |
| Beta | 0 |
| Outstanding Shares | 29,335,126 |
Return
| Return on Equity | -30.62% |
|---|---|
| Return on Assets | -15.37% |
| Return on Invested Capital | -13.22% |
Valuation & Multiples
| P/E Ratio | -4.37 |
|---|---|
| PEG | -0.5 |
| Price to Sales | 0.87 |
| Price to Book Ratio | 1.63 |
| Enterprise Value to Revenue | 23.24 |
| Enterprise Value to EBIT | -185.94 |
| Enterprise Value to Net Income | -133 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.28 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Sema4 Holdings Corp
3 employeesRelevant Senate Committees
This committee directly allocates discretionary federal spending, including funding for 'scientific research.' Its decisions directly impact the availability of government grants and contracts for R&D companies.
This committee has direct oversight of the NIH, a major funder of life sciences R&D, and the FDA, which regulates products emerging from life sciences research (e.g., diagnostics, research tools), even if not direct biotechnology.
This committee oversees intellectual property laws (patents, copyrights), which are foundational assets for any research and development company. Its antitrust oversight can also impact market structure for R&D firms.